Avenanthramide-C as Alzheimer’s Disease-Modifying Therapy: Early and Sustained Intervention Prevents Disease Progression in Mouse Models
Cells · 2025
DOI: 10.3390/cells14110826 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Alen Benhur Pravin Nathan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Chonnam National University Medical School, Gwangju 61469, Republic of Korea. Hauptthemen laut MEDLINE: Alzheimer Disease, ortho-Aminobenzoates, Disease Progression. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chonnam National University Hospital Biomedical Research Institute, Korea Dementia Research Project through the Korea Dementia Research Center (KDRC) funded by the Ministry of Health & Welfare and Ministry of Science and ICT, R…, The Basic Science Research Program through the National Research Foundation of Korea (NRF) The Ministry of Education.
Themen: Demenz
Abstract (Originalsprache)
Most approved drugs for Alzheimer’s disease (AD) are indicated for early to moderate stages and primarily target amyloid-beta or neurotransmitter systems. While these treatments may slow cognitive decline, they do not halt disease progression and are often limited by high cost and modest efficacy. Natural compounds are increasingly being explored as alternative interventions. Our previous study showed that oral administration of Avenanthramide-C (Avn-C), a natural polyphenol from oats, for 14 days from early AD stages improved cognition and reduced neuroinflammation in AD mice. To assess its long-term potential, in this study we extended Avn-C treatment to three months starting from early disease stages in 5xFAD and Tg2576 models. Sustained administration preserved recovered long-term potentiation (LTP) by maintaining AMPK activation and inhibiting caspase-3 and GSK3β, thereby reducing amyloid accumulation and tau hyperphosphorylation in the hippocampus. Avn-C also maintained anti-inflammatory effects by suppressing NF-κB-mediated proinflammatory cytokine release and preventing chronic microglial activation. This promoted microglial coverage of plaques in vivo and enhanced phagocytosis in vitro. Our findings suggest that early and sustained Avn-C treatment preserves cognitive function, modulates multiple pathological pathways, and may slow or prevent AD progression by targeting early neurodegenerative processes before irreversible damage occurs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Chonnam National University Medical School, Gwangju 61469, Republic of Korea.
- Department of Medicinal Biotechnology, College of Health Sciences, Dong-A University, Busan 49236, Republic of Korea.
- Department of Forensic Medicine, Chonnam National University Medical School, Gwangju 58128, Republic of Korea.
ORCID-Profile: Alen Benhur Pravin Nathan, Areeba Aziz, Semyeong Choi, Hyung-Seok Kim, Jonghyun Cho
Förderung
- Chonnam National University Hospital Biomedical Research Institute
- Korea Dementia Research Project through the Korea Dementia Research Center (KDRC) funded by the Ministry of Health & Welfare and Ministry of Science and ICT, R…
- The Basic Science Research Program through the National Research Foundation of Korea (NRF) The Ministry of Education
- KBRI basic research program through Korea Brain Research Institute funded by Ministry of Science and ICT
- The Electronics and Telecommunications Research Institute (ETRI) grant funded by the Korean government (MSIP)
- The BB21plus funded by Busan Metropolitan City and Busan Techno Park
- National Research Foundation of Korea (NRF) grant funded by the Korea Government (MEST)
- Korea Dementia Research Project through the Korea Dementia Research Center (KDRC) funded by the Ministry of Health & Welfare and Ministry of Science and IC…
Zitieren
APA
Nathan, A. B. P., Aziz, A., Choi, S., Lee, S., Jeon, S., Kim, H. S., Cho, J., & Jo, J. (2025). Avenanthramide-C as Alzheimer’s Disease-Modifying Therapy: Early and Sustained Intervention Prevents Disease Progression in Mouse Models. Cells. https://doi.org/10.3390/cells14110826
Vancouver
Nathan ABP, Aziz A, Choi S, Lee S, Jeon S, Kim HS, et al. Avenanthramide-C as Alzheimer’s Disease-Modifying Therapy: Early and Sustained Intervention Prevents Disease Progression in Mouse Models. Cells. 2025. doi:10.3390/cells14110826
BibTeX
@article{Nathan2025,
author = {Nathan, Alen Benhur Pravin and Aziz, Areeba and Choi, Semyeong and Lee, Seunghee and Jeon, Seyoung and Kim, Hyung-Seok and Cho, Jonghyun and Jo, Jihoon},
title = {Avenanthramide-C as Alzheimer’s Disease-Modifying Therapy: Early and Sustained Intervention Prevents Disease Progression in Mouse Models},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14110826}
}
EUVIMED